Sarepta Therapeutics (SRPT) Misses Q1 EPS by 15c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($1.15), $0.15 worse than the analyst estimate of ($1.00).

Sarepta said its pre-NDA meeting with the FDA remains calendared for second quarter 2015.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• LTC Properties (LTC) PT Raised to $52 at RBC Capital
• Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'